Literature DB >> 31048298

Chimeric Antigen Receptor T-Cell Therapy: What the Neuroradiologist Needs to Know.

H A Valand1, F Huda2, R K Tu3.   

Abstract

Chimeric antigen receptor T-cell therapy is an exciting and rapidly emerging "fifth pillar" treatment for hematologic cancers. Unique treatment-related toxicities and cost remain a major hindrance to its widespread application. The commonly faced challenges with this innovative therapy, its neurotoxicity, and manifestation on neuroimaging studies, are reviewed.
© 2019 by American Journal of Neuroradiology.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31048298      PMCID： PMC7053909          DOI： 10.3174/ajnr.A6042

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN： 0195-6108            Impact factor:   3.825


  14 in total

1.  Cost Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Relapsed or Refractory Pediatric B-Cell Acute Lymphoblastic Leukemia.

Authors:  John K Lin; Benjamin J Lerman; James I Barnes; Brian C Boursiquot; Yuan Jin Tan; Alex Q L Robinson; Kara L Davis; Douglas K Owens; Jeremy D Goldhaber-Fiebert
Journal:  J Clin Oncol       Date:  2018-09-13       Impact factor: 44.544

Review 2.  Patterns of contrast enhancement in the brain and meninges.

Authors:  James G Smirniotopoulos; Frances M Murphy; Elizabeth J Rushing; John H Rees; Jason W Schroeder
Journal:  Radiographics       Date:  2007 Mar-Apr       Impact factor: 5.333

3.  Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells.

Authors:  Juliane Gust; Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; David Myerson; Luis F Gonzalez-Cuyar; Cecilia Yeung; W Conrad Liles; Mark Wurfel; Jose A Lopez; Junmei Chen; Dominic Chung; Susanna Harju-Baker; Tahsin Özpolat; Kathleen R Fink; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Cancer Discov       Date:  2017-10-12       Impact factor: 39.397

Review 4.  Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Authors:  Sattva S Neelapu; Sudhakar Tummala; Partow Kebriaei; William Wierda; Cristina Gutierrez; Frederick L Locke; Krishna V Komanduri; Yi Lin; Nitin Jain; Naval Daver; Jason Westin; Alison M Gulbis; Monica E Loghin; John F de Groot; Sherry Adkins; Suzanne E Davis; Katayoun Rezvani; Patrick Hwu; Elizabeth J Shpall
Journal:  Nat Rev Clin Oncol       Date:  2017-09-19       Impact factor: 66.675

5.  Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

Review 6.  The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.

Authors:  Danny N Khalil; Eric L Smith; Renier J Brentjens; Jedd D Wolchok
Journal:  Nat Rev Clin Oncol       Date:  2016-03-15       Impact factor: 66.675

7.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

Review 8.  Cancer immunotherapy: Strategies for personalization and combinatorial approaches.

Authors:  Vishwanath Sathyanarayanan; Sattva S Neelapu
Journal:  Mol Oncol       Date:  2015-10-23       Impact factor: 6.603

9.  What a headache! Double-hit lymphoma with CNS recurrence - Role of chimeric antigen receptor (CAR) T-cell therapy.

Authors:  William Rafelson; Adam Olszewski
Journal:  Leuk Lymphoma       Date:  2019-11-25

10.  Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell.

Authors:  Marco Ruella; Jun Xu; David M Barrett; Joseph A Fraietta; Tyler J Reich; David E Ambrose; Michael Klichinsky; Olga Shestova; Prachi R Patel; Irina Kulikovskaya; Farzana Nazimuddin; Vijay G Bhoj; Elena J Orlando; Terry J Fry; Hans Bitter; Shannon L Maude; Bruce L Levine; Christopher L Nobles; Frederic D Bushman; Regina M Young; John Scholler; Saar I Gill; Carl H June; Stephan A Grupp; Simon F Lacey; J Joseph Melenhorst
Journal:  Nat Med       Date:  2018-10-01       Impact factor: 53.440
View more
  4 in total

1.  Use of Transcranial Doppler as a Biomarker of CAR T Cell-Related Neurotoxicity.

Authors:  Kathryn B Holroyd; Daniel B Rubin; Sarah LaRose; Andrew Monk; Sarah Nikiforow; Caron Jacobson; Henrikas Vaitkevicius
Journal:  Neurol Clin Pract       Date:  2022-02

Review 2.  Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies.

Authors:  Xiang Zhou; Leo Rasche; K Martin Kortüm; Sophia Danhof; Michael Hudecek; Hermann Einsele
Journal:  Front Immunol       Date:  2020-12-23       Impact factor: 7.561

3.  Language dysfunction-associated EEG findings in patients with CAR-T related neurotoxicity.

Authors:  Elisaveta Sokolov; Philipp Karschnia; Reuben Benjamin; Robert D M Hadden; Robert C D Elwes; Lee Drummond; Devyani Amin; Vitor Paiva; Alex Pennisi; Aline Herlopian; Matthew Frigault; Robin Sanderson; Shafqat Inam; Andrew J Cole; Jorg Dietrich
Journal:  BMJ Neurol Open       Date:  2020-06-18

4.  Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report.

Authors:  Kai Rejeski; Wolfgang G Kunz; Martina Rudelius; Veit Bücklein; Viktoria Blumenberg; Christian Schmidt; Philipp Karschnia; Florian Schöberl; Konstantin Dimitriadis; Louisa von Baumgarten; Joachim Stemmler; Oliver Weigert; Martin Dreyling; Michael von Bergwelt-Baildon; Marion Subklewe
Journal:  BMC Infect Dis       Date:  2021-01-28       Impact factor: 3.090
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.